Securities code: Chongqing Lummy Pharmaceutical Co.Ltd(300006) securities abbreviation: Chongqing Lummy Pharmaceutical Co.Ltd(300006) Announcement No.: 2022010 Chongqing Lummy Pharmaceutical Co.Ltd(300006) summary of 2021 Annual Report
1、 Important note: the summary of this annual report comes from the full text of the annual report. In order to fully understand the company's operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. All directors personally attended the meeting of the board of directors to consider this annual report. The audit opinion of Sichuan Huaxin (Group) accounting firm (special general partnership) on the company's financial report this year is: standard unqualified opinion. Tips of non-standard audit opinions □ applicable √ not applicable. The company is not profitable when it is listed and has not realized profits at present □ applicable √ not applicable to the profit distribution plan of ordinary shares or the plan of converting accumulation fund into share capital in the reporting period reviewed by the board of directors √ applicable □ not applicable. The profit distribution plan of ordinary shares reviewed and approved by the board of directors is: no cash dividend, no bonus shares, and no capital reserve into share capital. Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation Chongqing Lummy Pharmaceutical Co.Ltd(300006) stock code Chongqing Lummy Pharmaceutical Co.Ltd(300006)
Shenzhen Stock Exchange
Contact person and contact information: Secretary of the board of directors
Name: Cui Dan
Office address: 16th floor, building B, Chongqing Academy of science and technology, No. 2, Yangliu Road, Huangshan Avenue, Yubei District, Chongqing
Fax: 02367 Sino Wealth Electronic Ltd(300327)
Tel: 02367 Suzhou Slac Precision Equipment Co.Ltd(300382)
E-mail [email protected].
2. Introduction to main business or products during the reporting period
(I) main business
The company's main business is pharmaceutical manufacturing. The company's products have rich varieties and reasonable structure. The company's main products are chemical drugs, covering specialty categories (mainly including antitumor drugs, digestive system drugs, parenteral nutrition drugs), anti infection, etc. The key products of the company are as follows:
Nano carbon suspension injection (kanalin) is the only lymphatic tracer approved by CFDA. Kanalin has won " China National Chemical Engineering Co.Ltd(601117) excellent product brand of original drug and patented drug in pharmaceutical industry" for four consecutive years, " China National Chemical Engineering Co.Ltd(601117) excellent product brand of other drugs in pharmaceutical industry" for two consecutive years, and "single champion product in manufacturing industry (20192021)" Won many honorary titles such as "2021 China industry university research cooperation innovation and Promotion Award". The product has good lymphatic tropism and achieves the purpose of lymphatic tracing; It can also be used as a drug carrier to load drugs into the lymphatic system to achieve the purpose of lymphatic targeted therapy.
Esmeprazole enteric coated capsule (lemex), the first domestic esmeprazole oral preparation listed on the market and a national medical insurance variety, has won the title of " China National Chemical Engineering Co.Ltd(601117) excellent product brand of digestive system in pharmaceutical industry" for four consecutive years, and the honorary title of " China National Chemical Engineering Co.Ltd(601117) excellent product brand of original research medicine and patent medicine in pharmaceutical industry" for two consecutive years In January 2019, with the approval of China industry university research cooperation innovation and Promotion Award Office, lemesu won the "Excellence Award for innovation achievements of China industry university research cooperation in 2019". As a new generation of proton pump inhibitor (PPI), it has rapid, lasting and stable inhibition of gastric acid and high HP eradication rate.
In addition, the company's main products also include clindamycin hydrochloride injection, tranexamic acid sodium chloride injection, alanyl glutamine injection, tranexamic acid injection, naloxone hydrochloride for injection, alanyl glutamine for injection, fludarabine phosphate for injection, ramosetron hydrochloride injection, etc.
(II) business model
1. R & D mode
The company has established a multi-level scientific research and innovation system to build the company's follow-up core varieties from three dimensions: short-term, medium-term and long-term. In the short and medium term, the company will actively introduce high-quality projects and innovative technologies through investment platforms, and screen potential products and technologies that meet the company's development needs through strategic cooperation and equity investment. The technical center of the company continues to carry out the scientific research work of new drug imitation and innovation, focuses on the product development of advantageous segments in combination with the market and the actual situation of the company, further enriches the product portfolio of the company's segments and improves the company's competitiveness in this field. In the medium and long term, the company adheres to the path of independent R & D and innovation, focusing on promoting the subsequent upgrading products of kanalin developed by its subsidiary Yingrui pharmaceutical, such as nano carbon iron, etc; Kantsai independently develops products such as cellular immunotherapy or other personalized Innovation Medical Management Co.Ltd(002173) technologies.
2. Production mode
The company organizes production in strict accordance with relevant regulations to ensure drug quality, safety and effectiveness. The production department of the company is responsible for formulating the production plan, organizing production in strict accordance with the requirements of laws and regulations, ensuring that the production operation process meets the requirements of laws and regulations, and being responsible for the production process. The quality department of the company is responsible for the quality supervision of the whole process of drug production, and the quality inspection of raw and auxiliary materials, semi-finished products and finished products to ensure that the produced drugs meet the quality standards. The procurement and supply department of the company is responsible for the preparation of raw materials and packaging materials to ensure that they meet the requirements of the production plan.
3. Procurement mode
The purchase and supply department is mainly responsible for the purchase of materials related to the company's production, mainly including raw materials, packaging materials and other materials. The procurement and supply department shall formulate the procurement plan according to the annual and monthly production plans of the production department. In case of procurement demand, based on the previous market investigation, the procurement unit shall be selected and determined from the list of qualified suppliers through the negotiation process of quotation, inquiry and counter-offer, and the procurement contract shall be signed. The purchaser shall closely track and supervise all links of the execution of the purchase contract, and realize the whole process management from the supplier's confirmation of order, delivery, arrival, inspection, warehousing and use.
4. Sales model
The company's main business is drug production and sales. According to the product characteristics, the company has established a new business division and a chemical medicine division.
The new business division is responsible for the comprehensive promotion of the key product kanalin. The chemical medicine business department has two sales departments: Sales Department I and Sales Department II. The sales department I is mainly responsible for promoting the key products lemesu and esmeprazole sodium for injection, and the Sales Department II is mainly responsible for promoting the anti infection and other general medicine products. The company's sales team cooperates with state-owned, state-owned and listed large commercial companies to sell to hospitals and sales terminals at all levels. In order to comply with the trend of policy reform in the pharmaceutical industry, the company has strengthened the market promotion of key products, developed OTC terminal markets outside the hospital, continuously improved the market share and brand influence of relevant products, continuously optimized the product structure, strengthened the control over the terminal market, and carried out market development activities in an in-depth and orderly manner.
(III) performance drivers during the reporting period
The company's operating revenue in 2021 was 12252242 million yuan, a decrease of 22.63% over the same period last year, and the net profit attributable to the shareholders of the listed company was -1005282 million yuan. The performance loss in 2021 was mainly affected by the national centralized purchase policy, the increase of the company's R & D investment, non operating expenses and other comprehensive factors. Affected by the national centralized purchase policy, the sales volume and sales unit price of the company's key product esmeprazole enteric coated capsules decreased significantly, the sales revenue and profit decreased accordingly, and the provision for inventory falling price at the end of the year was about 27 million yuan; According to the judgment of the first instance of the company's wholly-owned subsidiaries Laimei pharmaceutical and Changchun Haiyue Pharmaceutical Co., Ltd. on the non distribution right of tadala, the net non operating income and expenditure of the company was -353773 million yuan.
During the reporting period, the company strengthened the development of the terminal market, accelerated the construction of OTC marketing channels, opened the promotion mode of convenience pharmacy, and reduced the sales impact of macro policies such as centralized procurement on lemex through the "out of hospital + in hospital" dual engine sales mode. With the gradual opening of all departments in major hospitals, kanalin has achieved a certain degree of growth with the basis of clinical application and expansion in other indication fields over the years. In the follow-up, the company concentrated its core resources, focused on the strategic development plan, actively introduced new products and technologies based on the subdivided fields of anti-tumor, digestive tract and anti infection, promoted the upgrading of marketing and technology, further refined and strengthened, and promoted the stable growth of the company's performance. 3. Main accounting data and financial indicators (1) whether the company needs to retroactively adjust or restate the accounting data of previous years in recent three years □ yes √ no
Unit: Yuan
Year end 2021 year end 2020 year end increase or decrease over the previous year year end 2019 year end
Total assets 292677393376314780297526 - 7.02% 350143103113
Net assets attributable to shareholders of listed companies 215634543592117132139083 84.10% 155599391139
20212020 year-on-year increase or decrease 2019
Operating income 122522418867158352991364 - 22.63% 185901075950
Net profit attributable to shareholders of listed company -10052817701 -32676495568 not applicable -15519817355
Deduction attributable to shareholders of listed companies not -13801214158 -37007944627 not applicable -18768890445
Net profit of recurring profit and loss
Net cash flow from operating activities 1082813024722453920006 - 51.78% 23129814063
Basic earnings per share (yuan / share) -0.1010 -0.4023 not applicable -0.1911
Diluted earnings per share (yuan / share) -0.1010 -0.4023 not applicable -0.1911
Weighted average return on net assets - 5.24% - 23.81%, 18.57% - 9.63%
(2) Quarterly main accounting data
Unit: Yuan
First quarter second quarter third quarter fourth quarter
Operating income 36028561595251682719532797323093233352354387
Net profit attributable to shareholders of listed companies: 4890633440 -1651363196 -1242351527 -12049736418
Deduction attributable to shareholders of listed companies is not -432580860 -2502392900 -2034753735 -8831486663
Net profit of recurring profit and loss
Net cash flow from operating activities 1076266457 -15712889657022387054206753981
Whether the above financial indicators or their total amount are significantly different from the financial indicators related to the quarterly report and semi annual report disclosed by the company □ yes √ No 4. Share capital and shareholders (1) ordinary shareholders and voting
